About Us
Our Story
Team
Careers
News
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Select specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Confirm Password
H
Idecabtagene Vicleucel vs. Ciltacabtagene Autoleucel: A Sophie's Choice for Patients With R/R MM
By
Hamza Hashmi
3 Videos
September 21, 2022
0 Comments
Login to view comments.
Click here to Login
Related Content
AUTOPLAY
ON
Total Health
Best of Hematology
Sat, Mar 25, 2023
12:38
SOHO 2022 Tenth Annual Meeting
SOHO 2022 DEBATE: Bispecific Antibodies vs. CAR-T for R/R MM - Defen…
Feat.
S. Usmani
04:08
CancerGRACE
CAR T-Cell Therapy Side Effects for Blood Cancers
Feat.
A. Goodman
31:51
Indy Hematology Review
Treating Multiple Myeloma: The Cure Is Within Reach - Goals of Curre…
Feat.
K. Anderson
15:54
Paul Richardson
Emerging Strategies in the Management of Relapsed MM
30:59
Houston Methodist Hospital
Overview of Advances in Multiple Myeloma
Feat.
S. Ganguly
21:38
Rahul Banerjee
CAR-T Therapy in Myeloma: What's Here and What's Coming So…
34:48
Kenneth Anderson
MM Cured in 2030 - What Are the Next Steps?
Feat.
K. Anderson
06:58
Saurabh Chhabra
Summary of the MAMMOTH Trial in R/R Myeloma
21:16
UChicago Medicine
Myeloma 2022: Challenges and Path Forward
Feat.
A. Jakubowiak
10:09
SOHO 2022 Tenth Annual Meeting
SOHO 2022: Next Questions for MM in the Coming 5-10 Years
Feat.
T. Martin
45:43
MedNews Week
Multiple Myeloma in 2022: Developments, Directions, and Disparities
Feat.
J. Mikhael
13:46
SOHO 2022 Tenth Annual Meeting
SOHO 2022: Bispecific T-Cell Engagers - Early Data and Where Will We…
Feat.
R. Orlowski
34:28
2022 Community Oncology Conference
Treatment Conundrums in Myeloma
Feat.
S. Giralt
24:01
ASH 2022 Conference Coverage
ASH 2022: First Relapse in Multiple Myeloma - How to Pick the Next B…
Feat.
Y. Efebera
33:28
Cleveland Clinic Taussig Cancer Institute
Management of Relapsed/Refractory Multiple Myeloma
Feat.
F. Anwer
14:41
Zhubin Gahvari
MAMMOTH Trial: Myeloma Outcomes Post Anti-CD38 MoAbs
10:34
SOHO 2022 Tenth Annual Meeting
SOHO 2022 Next Questions: Cellular Therapy
Feat.
K. Komanduri
06:16
ASH 2022 Conference Coverage
ASH 2022 U.S. Myeloma CAR-T Consortium Real World Experience: Factor…
Feat.
H. Hashmi
Shambavi Richard
Updates in Sequencing Treatment for Early Multiple Myeloma Relapse
12:11
SOHO 2022 Tenth Annual Meeting
SOHO 2022 DEBATE: Bispecific Antibodies vs. CAR-T for R/R MM - Pro C…
Feat.
T. Martin
